Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Operating Leases (2019 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Operating Leases for 7 consecutive years, with $12.6 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 2.12% to $12.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.6 million through Dec 2025, up 2.12% year-over-year, with the annual reading at $12.6 million for FY2025, 2.12% up from the prior year.
  • Operating Leases hit $12.6 million in Q4 2025 for Vanda Pharmaceuticals, up from $3.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $12.6 million in Q4 2025 to a low of $3.4 million in Q3 2025.
  • Historically, Operating Leases has averaged $8.3 million across 5 years, with a median of $8.6 million in 2022.
  • Biggest five-year swings in Operating Leases: soared 76.42% in 2024 and later tumbled 37.68% in 2025.
  • Year by year, Operating Leases stood at $10.1 million in 2021, then grew by 10.8% to $11.1 million in 2022, then tumbled by 37.12% to $7.0 million in 2023, then skyrocketed by 76.42% to $12.4 million in 2024, then rose by 2.12% to $12.6 million in 2025.
  • Business Quant data shows Operating Leases for VNDA at $12.6 million in Q4 2025, $3.4 million in Q3 2025, and $3.9 million in Q2 2025.